Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

621

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

August 31, 2011

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIOLOGICAL

BIIB019 (Daclizumab High Yield Process)

SC injection

DRUG

Placebo

Placebo SC injection

Trial Locations (56)

Unknown

Research Site, Brno

Research Site, Olomouc

Research Site, Pilsen

Research Site, Teplice

Research Site, Erlangen

Research Site, Marburg

Research Site, Osnabrück

Research Site, Regensburg

Research Site, Rostock

Research Site, Budapest

Research Site, Debrecen

Research Site, Esztergom

Research Site, Győr

Research Site, Kecskemét

Research Site, Miskolc

Research Site, Nyíregyháza

Research Site, Siófok

Research Site, Zalaegerszeg

Research Site, Andra-Pradeash

Research Site, Bangalore

Research Site, Chennai

Research Site, Kolkata

Research Site, Mumbai

Research Site, Rajasthan

Research Site, Visakhapatnam

Research Site, Bialystok

Research Site, Gdansk

Research Site, Katowice

Research Site, Krakow

Research Site, Lodz

Research Site, Lublin

Research Site, Warsaw

Research Site, Kazan'

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Saint Petersburg

Research Site, Samara

Research Site, Smolensk

Research Site, Ufa

Research Site, Yaroslavl

Research Site, Chernivtsi

Research Site, Dnipropetrovsk

Research Site, Donetsk

Research Site, Kharkiv

Research Site, Kiev

Research Site, Lviv

Research Site, Poltava

Research Site, Zaporizhzhya

Research Site, London

Research Site, Nottingham

Research Site, Plymouth

Research Site, Sheffield

Research Site, Stoke-on-Trent

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Biogen

INDUSTRY